Abstract
Neuroendocrine tumors (NETs) account for less than 3% of primary neoplasias of the pancreas. Despite success of the classification, the discovery of new methods of treatment, and innovations in the field of visualization, non-aeroendocrine neoplasms remain a clinically complex object, which is associated, among other things, with the lack of effective biomarkers for early diagnosis and monitoring of the course of the disease. This review is devoted to the analysis of current data on the molecular genetic features of pancreatic neuroendocrine tumors, taking into account the current WHO classification. The signaling pathways and individual markers that are being developed for the typing of NETs, the prognosis of the course of the disease, and the identification of potential targets for targeted therapy are discussed. The molecular bases of hereditary syndromes, which are associated with the development of NETs, are considered.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
